Biomedicines, Vol. 11, Pages 2951: Advances and Perspectives in Relation to the Molecular Basis of Diabetic Retinopathy—A Review

Biomedicines, Vol. 11, Pages 2951: Advances and Perspectives in Relation to the Molecular Basis of Diabetic Retinopathy—A Review

Biomedicines doi: 10.3390/biomedicines11112951

Authors: Michał Błaszkiewicz Agata Walulik Kamila Florek Ignacy Górecki Olga Sławatyniec Krzysztof Gomułka

Diabetes mellitus (DM) is a growing problem nowadays, and diabetic retinopathy (DR) is its predominant complication. Currently, DR diagnosis primarily relies on fundoscopic examination; however, novel biomarkers may facilitate that process and make it widely available. In this current review, we delve into the intricate roles of various factors and mechanisms in DR development, progression, prediction, and their association with therapeutic approaches linked to the underlying pathogenic pathways. Specifically, we focus on advanced glycation end products, vascular endothelial growth factor (VEGF), asymmetric dimethylarginine, endothelin-1, and the epigenetic regulation mediated by microRNAs (miRNAs) in the context of DR.